It emphasizes that your complete medical history, prior GI issues, and medication sensitivities should inform which route a prescriber ultimately chooses
Magid DJ, Wang Y, Herrin J, McNamara RL, Bradley EH, Curtis JP, Pollack CV, French WJ, Blaney ME, Krumholz HM
The company also reported adjusted EBITDA of $78.4 million in the third quarter, up 53% year over year
If your primary goal is weight management and you dont have diabetes, Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the FDA-approved options
The mechanism here is twofold
Ask during the consultation